P0J Stock Overview
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aptamer Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0075 |
| 52 Week High | UK£0.22 |
| 52 Week Low | UK£0.0005 |
| Beta | -0.42 |
| 1 Month Change | 25.00% |
| 3 Month Change | 1,400.00% |
| 1 Year Change | -91.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| P0J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 400.0% | 2.2% | -1.0% |
| 1Y | -91.6% | -22.2% | 2.2% |
Return vs Industry: P0J underperformed the German Biotechs industry which returned -22.2% over the past year.
Return vs Market: P0J underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| P0J volatility | |
|---|---|
| P0J Average Weekly Movement | 878.6% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: P0J's share price has been volatile over the past 3 months.
Volatility Over Time: P0J's weekly volatility has increased from 871% to 879% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 37 | n/a | aptamergroup.com |
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, and internationally. The company offers Optimer platform that enables the discovery and development of oligonucleotide binders; custom development services for oligonucleotide-based aptamer and Optimer binders; solutions to bioprocessing, diagnostic, and pharmaceutical scientists; and contract research services in the field of therapeutics. It serves pharma companies, diagnostic development companies, and research institutes.
Aptamer Group plc Fundamentals Summary
| P0J fundamental statistics | |
|---|---|
| Market cap | €3.68m |
| Earnings (TTM) | -€8.19m |
| Revenue (TTM) | €1.21m |
3.0x
P/S Ratio-0.4x
P/E RatioIs P0J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P0J income statement (TTM) | |
|---|---|
| Revenue | UK£1.04m |
| Cost of Revenue | UK£1.16m |
| Gross Profit | -UK£123.00k |
| Other Expenses | UK£6.89m |
| Earnings | -UK£7.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | -11.88% |
| Net Profit Margin | -677.39% |
| Debt/Equity Ratio | 5.7% |
How did P0J perform over the long term?
See historical performance and comparison